Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Last updated: April 16, 2013
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overall Status: Completed

Phase

3

Condition

Gastroesophageal Reflux Disease (Gerd)

Esophageal Disorders

Heartburn (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00992589
CR014836
RABGRD3004
  • Ages 1-11
  • All Genders

Study Summary

The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of suspected GERD, symptomatic GERD, or endoscopically or histologicallyproven GERD, based on frequent vomiting or regurgitation, with at least 1 of thefollowing: a) poor weight gain, or b) irritability, excessive crying or disturbedsleep that both the parent(s) and the doctor consider abnormal (but not due to colic)

  • or c) refusal to eat even if hungry or arching of the back during meals

  • weight 2.5 kg to 15.0 kg

  • I-GERQ-R score >16

  • Have only 1 caregiver in addition to the parent(s)

Exclusion

Exclusion Criteria:

  • History of confirmed acute life-threatening events due to GERD

  • Known narrowing of the opening from the stomach to the small intestines

  • Confirmed diagnosis of cow's milk allergy

  • Have taken PPIs or H2-blockers (a class of drugs that inhibit stomach acid production)or any of several drugs that affect the normal movement of the digestive tract (caffeine, theophylline, antacids, erythromycin, and others) within 3 days beforeentering the study

  • Have blood or urine test results that are well above or below the normal range for theinfant

Study Design

Total Participants: 344
Study Start date:
November 01, 2009
Estimated Completion Date:
November 30, 2011

Study Description

Rabeprazole sodium belongs to the class of drugs known as proton pump inhibitors, which suppress gastric acid secretion. The drug is approved in the United States for the treatment of adults with GERD and other acid-related gastrointestinal disorders, and has been studied in adolescents (older than 12 years of age) with results similar to those in adults. However, the drug has not been studied in children under the age of 12 years. This study focuses on the efficacy and safety of rabeprazole sodium in infants aged 1 to 11 months, the pediatric group in which the prevalence of GERD-related symptoms is the greatest. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group withdrawal study to compare the efficacy and safety of 2 doses (0.5 mg/kg or 1.0 mg/kg daily) of rabeprazole with placebo in the treatment of infants aged 1 to 11 months who have a diagnosis of suspected GERD, symptomatic GERD, or endoscopically or histologically proven GERD. The study consists of 3 study periods: a screening period of up to 10 days, an open-label treatment period of up to 3 weeks, and a 5-week double-blind treatment period. Patients who have been receiving GERD therapy before screening will have their GERD therapy discontinued for 3 days before entering the open-label treatment period. Patients who have a positive clinical response according to the Clinical Global Impressions - Improvement (CGI-I) scale at the end of the first or second week of the open-label treatment period will enter the double-blind treatment period; those who do not will be withdrawn from the study. A parent, legal guardian, or other individual experienced in the care of the infant will be the primary caregiver, who is responsible for the daily and weekly assessments and study drug administration. Efficacy assessments consist of the Infant Gastroesophageal Reflux Questionnaire Revised (I GERQ-R) total score, the Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I GERQ-DD) total score, the CGI-I, the Global Treatment Satisfaction Score, and the weight-for-age Z-score. Safety assessments include monitoring of concomitant therapies and adverse events throughout the study; clinical laboratory testing (hematology, clinical chemistry, urinalysis), measurement of vital signs (pulse and respiratory rate, blood pressure, temperature); and physical examination including length and weight. The study hypothesis is that rabeprazole sodium is superior to placebo in the treatment of GERD in infants aged 1 to 11 months. Rabeprazole sodium capsule(s) by mouth once a day, 10.0 milligram (mg)/kilogram (kg) for up to 3 weeks during the open-label treatment period and either 5.0 mg/kg or 10.0 mg/kg during the 5-week double-blind treatment period. To give the study drug to the infants, the contents of the capsule(s) are sprinkled onto a small amount of soft food or, as needed, the contents of the capsule(s) may be given in a small amount (5 milliliter [mL]) of infant formula or expressed breast milk.

Connect with a study center

  • Garran,
    Australia

    Site Not Available

  • Herston,
    Australia

    Site Not Available

  • Kogarah,
    Australia

    Site Not Available

  • Parkville,
    Australia

    Site Not Available

  • Sydney,
    Australia

    Site Not Available

  • Antwerpen,
    Belgium

    Site Not Available

  • Brussel,
    Belgium

    Site Not Available

  • Leuven,
    Belgium

    Site Not Available

  • Pleven,
    Bulgaria

    Site Not Available

  • empty

    Plovdiv N/A,
    Bulgaria

    Site Not Available

  • empty

    Sofia,
    Bulgaria

    Site Not Available

  • empty

    Frederiksberg,
    Denmark

    Site Not Available

  • Odense,
    Denmark

    Site Not Available

  • empty

    Viborg,
    Denmark

    Site Not Available

  • empty

    Bordeaux,
    France

    Site Not Available

  • empty

    Bron,
    France

    Site Not Available

  • empty

    Lille,
    France

    Site Not Available

  • empty

    Tours,
    France

    Site Not Available

  • empty

    Hamburg,
    Germany

    Site Not Available

  • empty

    Zwickau,
    Germany

    Site Not Available

  • Budapest,
    Hungary

    Site Not Available

  • empty

    Békéscsaba,
    Hungary

    Site Not Available

  • Békéscsaba,
    Hungary

    Site Not Available

  • Gyulai Ut 18,
    Hungary

    Site Not Available

  • empty

    Gyõr,
    Hungary

    Site Not Available

  • Gyõr,
    Hungary

    Site Not Available

  • Miskolc,
    Hungary

    Site Not Available

  • Nyiregyhaza,
    Hungary

    Site Not Available

  • Pecs,
    Hungary

    Site Not Available

  • empty

    Sopron,
    Hungary

    Site Not Available

  • Szombathely,
    Hungary

    Site Not Available

  • Veszprem,
    Hungary

    Site Not Available

  • empty

    Veszprém,
    Hungary

    Site Not Available

  • Veszprém,
    Hungary

    Site Not Available

  • empty

    Indore,
    India

    Site Not Available

  • empty

    Kolkata,
    India

    Site Not Available

  • empty

    Maharai,
    India

    Site Not Available

  • empty

    New Dehli,
    India

    Site Not Available

  • empty

    Pune,
    India

    Site Not Available

  • empty

    Visakhapatnam,
    India

    Site Not Available

  • Haifa,
    Israel

    Site Not Available

  • empty

    Holon,
    Israel

    Site Not Available

  • Jerusalem,
    Israel

    Site Not Available

  • Petach Tikva,
    Israel

    Site Not Available

  • Petach Tikvah,
    Israel

    Site Not Available

  • Ramat Gan,
    Israel

    Site Not Available

  • Tiberias,
    Israel

    Site Not Available

  • Amsterdam,
    Netherlands

    Site Not Available

  • empty

    Amsterdam Nl,
    Netherlands

    Site Not Available

  • Nijmegen,
    Netherlands

    Site Not Available

  • Zwolle,
    Netherlands

    Site Not Available

  • Bialystok,
    Poland

    Site Not Available

  • Bydgoszcz,
    Poland

    Site Not Available

  • Bydgoszcz N/A,
    Poland

    Site Not Available

  • empty

    Bytom,
    Poland

    Site Not Available

  • Czestochowa,
    Poland

    Site Not Available

  • empty

    Kraków,
    Poland

    Site Not Available

  • empty

    Lodz,
    Poland

    Site Not Available

  • empty

    Poznan,
    Poland

    Site Not Available

  • Rzeszow,
    Poland

    Site Not Available

  • Rzeszow N/A,
    Poland

    Site Not Available

  • Torun,
    Poland

    Site Not Available

  • Warszawa,
    Poland

    Site Not Available

  • empty

    Wroclaw,
    Poland

    Site Not Available

  • empty

    000775 Durbanville,
    South Africa

    Site Not Available

  • empty

    007925 Wynberg,
    South Africa

    Site Not Available

  • empty

    Benoni,
    South Africa

    Site Not Available

  • Durban,
    South Africa

    Site Not Available

  • Durbanville,
    South Africa

    Site Not Available

  • empty

    Midrand,
    South Africa

    Site Not Available

  • Panorama,
    South Africa

    Site Not Available

  • empty

    Pretoria,
    South Africa

    Site Not Available

  • Wynberg,
    South Africa

    Site Not Available

  • empty

    Malmö,
    Sweden

    Site Not Available

  • empty

    Stockholm,
    Sweden

    Site Not Available

  • empty

    Sundsvall,
    Sweden

    Site Not Available

  • Birmingham, Alabama
    United States

    Site Not Available

  • Columbiana, Alabama
    United States

    Site Not Available

  • Dothan, Alabama
    United States

    Site Not Available

  • Huntsville, Alabama
    United States

    Site Not Available

  • Mobile, Alabama
    United States

    Site Not Available

  • Phoenix, Arizona
    United States

    Site Not Available

  • Bentonville, Arkansas
    United States

    Site Not Available

  • Orange, California
    United States

    Site Not Available

  • empty

    San Francisco, California
    United States

    Site Not Available

  • Centennial, Colorado
    United States

    Site Not Available

  • Thornton, Colorado
    United States

    Site Not Available

  • Maitland, Florida
    United States

    Site Not Available

  • Miami, Florida
    United States

    Site Not Available

  • empty

    Atlanta, Georgia
    United States

    Site Not Available

  • Augusta, Georgia
    United States

    Site Not Available

  • Park Ridge, Illinois
    United States

    Site Not Available

  • Indianapolis, Indiana
    United States

    Site Not Available

  • Louisville, Kentucky
    United States

    Site Not Available

  • Owensboro, Kentucky
    United States

    Site Not Available

  • New Orleans, Louisiana
    United States

    Site Not Available

  • Shreveport, Louisiana
    United States

    Site Not Available

  • Boston, Massachusetts
    United States

    Site Not Available

  • empty

    Waltham, Massachusetts
    United States

    Site Not Available

  • Worcester, Massachusetts
    United States

    Site Not Available

  • Flint, Michigan
    United States

    Site Not Available

  • empty

    Southfield, Michigan
    United States

    Site Not Available

  • St. Paul, Minnesota
    United States

    Site Not Available

  • Jackson, Mississippi
    United States

    Site Not Available

  • Bridgeton, Missouri
    United States

    Site Not Available

  • empty

    Omaha, Nebraska
    United States

    Site Not Available

  • empty

    Las Vegas, Nevada
    United States

    Site Not Available

  • empty

    Long Branch, New Jersey
    United States

    Site Not Available

  • Mays Landing, New Jersey
    United States

    Site Not Available

  • Valhalla, New Jersey
    United States

    Site Not Available

  • Bronx, New York
    United States

    Site Not Available

  • empty

    Brooklyn, New York
    United States

    Site Not Available

  • Buffalo, New York
    United States

    Site Not Available

  • Utica, New York
    United States

    Site Not Available

  • Charlotte, North Carolina
    United States

    Site Not Available

  • empty

    Columbus, Ohio
    United States

    Site Not Available

  • Toledo, Ohio
    United States

    Site Not Available

  • Youngstown, Ohio
    United States

    Site Not Available

  • empty

    Oklahoma City, Oklahoma
    United States

    Site Not Available

  • Gresham, Oregon
    United States

    Site Not Available

  • empty

    Danville, Pennsylvania
    United States

    Site Not Available

  • Hershey, Pennsylvania
    United States

    Site Not Available

  • empty

    Wilkes Barre, Pennsylvania
    United States

    Site Not Available

  • Chattanooga, Tennessee
    United States

    Site Not Available

  • Kingsport, Tennessee
    United States

    Site Not Available

  • Dallas, Texas
    United States

    Site Not Available

  • Laredo, Texas
    United States

    Site Not Available

  • empty

    Longview, Texas
    United States

    Site Not Available

  • San Antonio, Texas
    United States

    Site Not Available

  • Tomball, Texas
    United States

    Site Not Available

  • Fairfax, Virginia
    United States

    Site Not Available

  • empty

    Vienna, Virginia
    United States

    Site Not Available

  • Huntington, West Virginia
    United States

    Site Not Available

  • empty

    Morgantown, West Virginia
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.